Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The interferons in haematological malignancies

F Mandelli1, W Arcese, G Avvisati

  • 1Department of Human Biopathology, University La Sapienza, Rome, Italy.

Bailliere'S Clinical Haematology
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).

Bone marrow transplantation·2001
Same author

Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group.

Annals of oncology : official journal of the European Society for Medical Oncology·2001
Same author

Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia.

British journal of haematology·2001
Same author

Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies.

Leukemia·2001
Same author

Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995.

Leukemia·2001
Same author

Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors.

Seminars in hematology·2001

Interferons-alpha (IFNs-alpha) show significant efficacy in treating various blood cancers like hairy cell leukaemia and chronic myeloid leukaemia. While beneficial for some hematologic malignancies, their role in others remains under investigation.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Interferons (IFNs) are biological response modifiers impacting cellular proliferation and immunoregulation.
  • Their therapeutic potential in hematologic malignancies has been extensively investigated over the past decade.

Purpose of the Study:

  • To review the efficacy of Interferons-alpha (IFNs-alpha) in treating various hematologic malignancies.
  • To consolidate existing findings on IFN therapy outcomes across different blood cancers.

Main Methods:

  • Systematic review of studies investigating IFN-alpha therapy in hematologic malignancies.
  • Analysis of response rates and impact on disease progression for different conditions.

Main Results:

Related Experiment Videos

  • IFNs-alpha demonstrate significant efficacy in hairy cell leukaemia and chronic myeloid leukaemia, altering disease natural history.
  • Beneficial effects observed in low-grade lymphoma, cutaneous T-cell lymphoma, and multiple myeloma for induction and maintenance.
  • Confirmed efficacy in essential thrombocythaemia and polycythaemia vera.

    • Conclusions:

    • IFNs-alpha have a well-established role in managing several hematologic malignancies.
    • The role of IFNs in chronic lymphocytic leukaemia and myelofibrosis with myeloid metaplasia requires further research due to controversial findings.